(Q37951502)

25 August 2017

Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

25 August 2017

1 reference

1 reference

1 reference

Anna Simona Sasdelli

3

0 references

Giulio Marchesini

object named as

Giulio Marchesini

series ordinal

4

0 references

author name string

Simona Moscatiello

series ordinal

1

1 reference

PubMed ID

22043839

25 August 2017

Raffaella Di Luzio

series ordinal

2

1 reference

PubMed ID

22043839

25 August 2017

language of work or name

English

0 references

publication date

1 November 2011

1 reference

Expert Opinion on Pharmacotherapy

25 August 2017

1 reference

25 August 2017

12

1 reference

25 August 2017

17

1 reference

25 August 2017

2657-2672

1 reference

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

25 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The metabolic syndrome--a new worldwide definition

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; Internat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Liver fat in the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Nonalcoholic fatty liver disease: a feature of the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Increased risk of cardiovascular disease in non-alcoholic fatty liver disease: causal effect or epiphenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The association between increased alanine aminotransferase activity and metabolic factors in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Chronological development of elevated aminotransferases in a nonalcoholic population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Unexplained elevations in alanine aminotransferase in individuals with the metabolic syndrome: results from the third National Health and Nutrition Survey (NHANES III).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Risk of severe liver disease in nonalcoholic fatty liver disease with normal aminotransferase levels: a role for insulin resistance and diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Independent associations between liver fat, visceral adipose tissue, and metabolic risk factors in men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Relative contribution of iron burden, HFE mutations, and insulin resistance to fibrosis in nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Fatty liver in type 2 diabetes mellitus: relation to regional adiposity, fatty acids, and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Lifestyle modification for the management of obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Impact of weight loss on the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Impact of weight loss on the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The effect of metformin and intensive lifestyle intervention on the metabolic syndrome: the Diabetes Prevention Program randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

One-year intense nutritional counseling results in histological improvement in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Selected practical issues in their evaluation and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effect of changes on body weight and lifestyle in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Modest weight loss and physical activity in overweight patients with chronic liver disease results in sustained improvements in alanine aminotransferase, fasting insulin, and quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Exercise and diet induced weight loss improves measures of oxidative stress and insulin sensitivity in adults with characteristics of the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Fructose consumption as a risk factor for non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Mitochondrial dysfunction and insulin resistance: a matter of lifestyle?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Exercise training amount and intensity effects on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Bariatric surgery: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Bariatric surgery as a novel treatment for type 2 diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Drug treatment of the overweight patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Weight loss induced by orlistat reverses fatty infiltration and improves hepatic fibrosis in obese patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Orlistat for overweight subjects with nonalcoholic steatohepatitis: A randomized, prospective trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Randomized trial of lifestyle modification and pharmacotherapy for obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effect of rimonabant on the high-triglyceride/ low-HDL-cholesterol dyslipidemia, intraabdominal adiposity, and liver fat: the ADAGIO-Lipids trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Pioglitazone for diabetes prevention in impaired glucose tolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effect of pioglitazone on pancreatic beta-cell function and diabetes risk in Hispanic women with prior gestational diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Serum antioxidant status is associated with metabolic syndrome among U.S. adults in recent national surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Incretin mimetics as a novel therapeutic option for hepatic steatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The farnesoid X receptor (FXR) as a new target in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Farnesoid X receptor is essential for normal glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance: the Medical Research Council Ely Prospective Study 1990-2000

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The role of vitamin D and calcium in type 2 diabetes. A systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Traditional chinese medicine in treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Berberine: a potential phytochemical with multispectrum therapeutic activities

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Effect of chromium supplementation on glucose metabolism and lipids: a systematic review of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Plasma copper, zinc, and selenium levels and correlates with metabolic syndrome components of lebanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Zinc, a regulator of islet function and glucose homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Risk of cardiovascular disease in patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Components of metabolic syndrome are independent predictors of mortality in patients with chronic liver disease: a population-based study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Serum 25-Hydroxyvitamin D Concentration and Subsequent Risk of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

The role of physical activity and fitness in the prevention and treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

Cognitive-behavioral treatment of nonalcoholic Fatty liver disease: a propensity score-adjusted observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14656566.2011.629188

10.1517/14656566.2011.629188

21 January 2018

Identifiers

DOI

1 reference

25 August 2017

1 reference

PubMed ID

22043839